Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH
Madrigal Pharma's REZDIFFRA achieved $100-$103M in Q4 sales, marking 61% growth, with market penetration of only 4% relative to TAM, indicating blockbuster potential. Potential competition from GLP-1 drugs and other MASH therapies exists, but REZDIFFRA's combination use and first-mover advantage mitigate these risks. Analysts project $515M in 2025 sales, driven by Medicare coverage, low market penetration, and European launch, making MDGL stock a STRONG BUY.
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week
An estimates-beating set of preliminary financial numbers and two bullish analyst updates weren't enough to lift Madrigal Pharmaceuticals (MDGL -0.59%) stock out of the doldrums over the past few trading days. Investor expectations are clearly very high, as the company's share price had withered by nearly 20% week to date as of Friday before market open, according to data compiled by S&P Global Market Intelligence.
MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales
Madrigal stock slides 10% as the preliminary Q4 Rezdiffra sales figures failed to impress investors.
Why Madrigal Pharmaceuticals Stock Is Sinking Today
Shares of Madrigal Pharmaceuticals (MDGL -13.81%) were sinking 13.3% lower as of 11:11 a.m. ET on Monday.
Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion
Rezdiffra's strong launch has been confirmed by robust sales in the first two quarters, even though it may have only been used in 2% of its current target patient population. Competitors with MASH therapies like NVO, SGMT, ALT and Boehringer Ingelheim are making progress, although the possibility of combinations could limit any downside for MDGL. There is ongoing discussion about a potential buyout, adding another layer of interest for investors, and a potential EU launch in H2'25.
Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?
Madrigal Pharmaceuticals, Inc. (MDGL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MDGL's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Wall Street Analysts Believe Madrigal (MDGL) Could Rally 26.44%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in Madrigal (MDGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More
There's a bright future ahead for this company.
Here's Why Madrigal (MDGL) is a Great Momentum Stock to Buy
Does Madrigal (MDGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion
Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval, positioning it as a foundational therapy for NASH with advanced fibrosis. Broad insurance coverage and allowance for non-invasive testing [NIT] enhance patient accessibility and Rezdiffra's adoption rate. Competition from Novo Nordisk's Semaglutide poses a market risk, but Rezdiffra's liver-specific mechanism offers a targeted advantage.
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
MDGL stock is up as the company reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates
Madrigal (MDGL) came out with a quarterly loss of $4.92 per share versus the Zacks Consensus Estimate of a loss of $6.94. This compares to loss of $5.34 per share a year ago.
